Kenya has been chosen as one of three African countries to participate in a major vaccine trial aimed at testing the effectiveness of the MTBVAC vaccine in preventing tuberculosis (TB) among adolescents and adults with latent TB infection.
This medical trial is being conducted by IAVI, a global research organization, in partnership with Biofabri.
In an official statement, IAVI announced that the trial, named IMAGINE (Investigation of MTBVAC toward Accelerating Global Immunization for a Neglected Epidemic), is a Phase 2b clinical trial that will involve 4,300 participants across 15 locations in Kenya, South Africa, and Tanzania.
The main goal of this study is to assess how well the MTBVAC vaccine can prevent TB in people who already have a latent TB infection, which means they have TB bacteria in their body but do not show symptoms and are not contagious.
Kenya’s Role in the Vaccine Trial
In Kenya, the trial will be carried out at two key medical research institutions:
- Kenya Medical Research Institute (KEMRI) / Center for Respiratory Disease Research in Nairobi.
- Victoria Biomedical Research Institute in Kisumu.
According to the statement, “MTBVAC is a promising vaccine candidate being evaluated in the IMAGINE trial, a large-scale study focused on testing its safety and effectiveness in preventing TB disease in adolescents and adults with latent TB infection in Kenya, Tanzania, and South Africa.”
Understanding Tuberculosis and Its Impact
Tuberculosis (TB) is a bacterial infection that primarily affects the lungs and spreads through the air when an infected person coughs, sneezes, or spits. The disease remains one of the leading global health threats.
In 2023, the World Health Organization (WHO) estimated that 10.8 million people worldwide contracted TB, with the breakdown being:
- 6.0 million men
- 3.6 million women
- 1.3 million children
In Kenya, data from the Kenya Demographic Health Survey (KDHS) 2022 shows that 1.1% of the country’s population is currently suffering from TB.
What is Latent TB Infection (LTBI)?
Latent Tuberculosis Infection (LTBI) occurs when TB bacteria are present in the body but remain inactive. People with latent TB do not experience symptoms and cannot spread the disease. However, they are at risk of developing active TB later in life. According to WHO, approximately one-quarter of the world’s population is infected with TB bacteria, and about 5–10% of these individuals will eventually develop active TB disease.
The Need for a New TB Vaccine
Currently, the only TB vaccine available is the Bacillus Calmette-Guérin (BCG) vaccine, which is primarily given to infants and provides only partial protection. However, it does not effectively prevent TB in adolescents or adults, highlighting the urgent need for a more effective vaccine.
“A vaccine that can protect children, teenagers, and adults from TB would save millions of lives,” IAVI emphasized in its statement.
Promising Results of the MTBVAC Vaccine
IAVI reports that MTBVAC, which is designed as a single-dose vaccine, has shown encouraging results in previous trials. The Phase 2 trial demonstrated that MTBVAC had similar immune responses and safety levels at different dosage levels compared to the widely used BCG vaccine.
Dr. Lewis Schrager, who leads IAVI’s TB vaccine research, described the new IMAGINE trial as a crucial step toward fighting one of the deadliest diseases in the world. He stated, “The IMAGINE trial is an important new effort to develop a vaccine capable of combating TB, a disease that continues to claim millions of lives worldwide.”
As the trial progresses in Kenya, South Africa, and Tanzania, researchers hope that the MTBVAC vaccine will prove to be a groundbreaking solution in the fight against TB, offering long-term protection and helping reduce the global burden of this infectious disease.
Join Gen Z official Whatsapp Channel To Stay Updated On time the ongoing situation https://whatsapp.com/channel/0029VaWT5gSGufImU8R0DO30
